Close Menu


Rosetta's president and CEO also noted that the company continues to work in the miRNA therapeutics space, but indicated that its collaboration with Regulus Therapeutics to develop a liver cancer drug has officially ended.

The application, owned by Stanford University and exclusively licensed to Regulus, claims methods of antagonizing miR-181a to regulate immune response.

The Belgian university will use the WaferGen system in validating a biomarker signature for neuroblastoma in children, as well as other applications.

The awards will support projects investigating the roles the small, non-coding RNAs play in cancer and asthma.

IP Update: Mar 11, 2010


USPTO Publishes Three Patents, Five Patent Applications Related to RNAi

The protocol may better enable researchers in other labs to conduct microRNA biomarker research, and is an incremental step toward developing a blood-based cancer detection method based on circulating microRNAs.

Wendel and colleagues used a short hairpin library screen to identify genes whose knockdown mimicked the effect of microRNA-19, a member of the oncogenic miR-17-92 cluster, in lymphocytes, hypothesizing that this would reveal the genes responsible for the miRNA's activity.

Papers of Note: Mar 4, 2010


RNAi- and microRNA-Related Papers Published February 2010

IP Update: Mar 4, 2010


USPTO Publishes One Patent, Ten Patent Applications Related to RNAi

Febit, ZyGem


The Washington Post reports on researchers' efforts to determine the effect of an increasingly common SARS-CoV-2 mutation.

Florida Politics reports Florida's law barring life, long-term care, and disability insurers from using genetic information in coverage decisions went into effect at the beginning of July.

A new analysis finds a link between popular media coverage of a scientific study and how often that paper is cited.

In Nature this week: CRISPR approaches to editing plant genomes, way to speed up DNA-PAINT, and more.